Clinical trial · no report yet · Phase 3
STELLAR-303
Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer
- NCT05425940 ↗
- Active not recruiting
- Exelixis
- 92 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 43 | |
| YouTube | 31 | |
| Podcasts | 15 | |
| X videos | 3 |
The trial
ClinicalTrials.gov- Official title
- A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Colorectal Cancer
- Interventions
- XL092; Atezolizumab; Regorafenib
- Arms
- XL092 + Atezolizumab · Experimental
- Regorafenib · Active comparator
- Enrollment
- 901
- Primary outcomes
- Overall Survival (OS) of XL092 + Atezolizumab Versus Regorafenib in All Randomized Participants
- Overall Survival (OS) of XL092 + Atezolizumab Versus Regorafenib in Randomized Non-Liver Metastases (NLM) Participants
- Sponsor
- Exelixis
- Start
- Sep 7, 2022
- Primary completion
- Jun 16, 2026
- Results posted
- No
- Registry record
- NCT05425940 · updated Jul 17, 2026
Publications
linked from the registry- Hecht JR, Park YS, Tabernero J, Lee MA, Lee S, Virgili AC, Van den Eynde M, Fontana E, Fakih M, Asghari G, So J, Stein A, Dubreuil O, Bodnar L, He CS, Wang G, Smith R, Eng C, Saeed A; STELLAR-303 study investigators. Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial. Lancet. 2025 Nov 15;406(10517):2360-2370. doi: 10.1016/S0140-6736(25)02025-2. Epub 2025 Oct 20. PubMed 41130252
- Saeed A, Tabernero J, Parikh A, Van den Eynde M, Karthaus M, Gerlinger M, Wang Z, Wang G, Smith R, Hecht JR. STELLAR-303: randomized phase III study of zanzalintinib + atezolizumab in previously treated metastatic colorectal cancer. Future Oncol. 2024;20(24):1733-1743. doi: 10.1080/14796694.2024.2352276. Epub 2024 Jul 23. PubMed 39041200